Changchun High-tech (000661.SZ): The clinical trial application for the oral suspension of medroxyprogesterone acetate (MESHY Asia) has been approved.

Wisdom Financial News APP, Changchun High-tech (000661.SZ) announced recently that its subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd. (hereinafter referred to as "Jinsai Pharmaceutical"), has received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration, authorizing the overseas production drug registration clinical trial application for the distribution cooperation product Mifepristone Acetate Oral Suspension (Mysia) to be approved.